Werewolf Therapeutics (NASDAQ:HOWL) Earns “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Werewolf Therapeutics (NASDAQ:HOWL) in a research note released on Friday morning, Benzinga reports. HC Wainwright currently has a $15.00 price objective on the stock.

HOWL has been the topic of several other research reports. Wedbush restated an outperform rating and set a $9.00 price objective on shares of Werewolf Therapeutics in a report on Monday, May 6th. JMP Securities restated a market outperform rating and issued a $12.00 target price on shares of Werewolf Therapeutics in a report on Monday, May 6th.

Werewolf Therapeutics Price Performance

HOWL stock opened at $4.88 on Friday. The company has a debt-to-equity ratio of 0.24, a current ratio of 6.71 and a quick ratio of 6.71. The company’s 50-day moving average is $5.71 and its 200-day moving average is $4.96. The stock has a market capitalization of $212.06 million, a PE ratio of -4.48 and a beta of 0.71. Werewolf Therapeutics has a 1 year low of $1.57 and a 1 year high of $8.19.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings results on Friday, May 3rd. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.04). Werewolf Therapeutics had a negative return on equity of 36.15% and a negative net margin of 256.33%. The firm had revenue of $0.74 million during the quarter, compared to the consensus estimate of $5.00 million. Equities research analysts expect that Werewolf Therapeutics will post -1.52 EPS for the current fiscal year.

Hedge Funds Weigh In On Werewolf Therapeutics

Hedge funds have recently bought and sold shares of the company. Janus Henderson Group PLC bought a new position in shares of Werewolf Therapeutics during the first quarter valued at about $10,922,000. PFM Health Sciences LP lifted its position in shares of Werewolf Therapeutics by 35.6% during the 4th quarter. PFM Health Sciences LP now owns 3,468,177 shares of the company’s stock worth $13,387,000 after buying an additional 909,895 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Werewolf Therapeutics by 26.8% in the 1st quarter. Vanguard Group Inc. now owns 1,107,347 shares of the company’s stock worth $7,176,000 after buying an additional 233,909 shares during the last quarter. Acadian Asset Management LLC grew its holdings in shares of Werewolf Therapeutics by 119.8% in the first quarter. Acadian Asset Management LLC now owns 172,883 shares of the company’s stock valued at $1,119,000 after acquiring an additional 94,212 shares in the last quarter. Finally, Denali Advisors LLC bought a new stake in Werewolf Therapeutics during the first quarter worth $172,000. 64.84% of the stock is owned by hedge funds and other institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.